AR093939A1 - Composiciones que comprenden vortioxetina y donepezil - Google Patents

Composiciones que comprenden vortioxetina y donepezil

Info

Publication number
AR093939A1
AR093939A1 ARP130104651A ARP130104651A AR093939A1 AR 093939 A1 AR093939 A1 AR 093939A1 AR P130104651 A ARP130104651 A AR P130104651A AR P130104651 A ARP130104651 A AR P130104651A AR 093939 A1 AR093939 A1 AR 093939A1
Authority
AR
Argentina
Prior art keywords
compositions
donepezil
vortioxetina
vortioxetine
treatment
Prior art date
Application number
ARP130104651A
Other languages
English (en)
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR093939A1 publication Critical patent/AR093939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proveen composiciones farmacéuticas que comprenden vortioxetina y donepezil, y el uso de dichas composiciones para el tratamiento de disfunciones cognitivas.
ARP130104651A 2012-12-13 2013-12-12 Composiciones que comprenden vortioxetina y donepezil AR093939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
AR093939A1 true AR093939A1 (es) 2015-07-01

Family

ID=49943326

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130104651A AR093939A1 (es) 2012-12-13 2013-12-12 Composiciones que comprenden vortioxetina y donepezil
ARP220101337A AR125920A2 (es) 2012-12-13 2022-05-19 Composiciones que comprenden vortioxetina y donepezil

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220101337A AR125920A2 (es) 2012-12-13 2022-05-19 Composiciones que comprenden vortioxetina y donepezil

Country Status (44)

Country Link
US (1) US9211288B2 (es)
EP (1) EP2931276B1 (es)
JP (1) JP6257641B2 (es)
KR (1) KR102171152B1 (es)
CN (1) CN104853755B (es)
AP (1) AP2015008498A0 (es)
AR (2) AR093939A1 (es)
AU (1) AU2013357308B2 (es)
BR (1) BR112015013675B1 (es)
CA (1) CA2893468C (es)
CL (1) CL2015001615A1 (es)
CR (1) CR20150303A (es)
CY (1) CY1120098T1 (es)
DK (1) DK2931276T3 (es)
DO (1) DOP2015000133A (es)
EA (1) EA028300B1 (es)
EC (1) ECSP15023182A (es)
ES (1) ES2663680T3 (es)
GE (1) GEP201706739B (es)
GT (1) GT201500143A (es)
HK (1) HK1212601A1 (es)
HR (1) HRP20180333T1 (es)
HU (1) HUE036280T2 (es)
IL (1) IL239192B (es)
LT (1) LT2931276T (es)
MA (1) MA38253B1 (es)
ME (1) ME03029B (es)
MX (1) MX362886B (es)
MY (1) MY171802A (es)
NI (1) NI201500078A (es)
NO (1) NO2970700T3 (es)
NZ (1) NZ708595A (es)
PE (1) PE20151026A1 (es)
PH (1) PH12015501302B1 (es)
PL (1) PL2931276T3 (es)
PT (1) PT2931276T (es)
RS (1) RS56949B1 (es)
RU (1) RU2635528C2 (es)
SG (1) SG11201504483YA (es)
SI (1) SI2931276T1 (es)
TN (1) TN2015000235A1 (es)
UA (1) UA114016C2 (es)
WO (1) WO2014090929A1 (es)
ZA (1) ZA201504274B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
BR112018000841A8 (pt) * 2015-07-17 2022-11-22 Pasteur Institut Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
AU2017407364B2 (en) 2017-03-30 2019-11-07 Rundle Research, LLC Methods of treating depression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
KR100195399B1 (ko) 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (es) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
CN1215399A (zh) 1996-04-12 1999-04-28 赫彻斯特马里恩鲁斯公司 作为乙酰胆碱酯酶抑制剂及止痛药的靛红衍生物
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2003082820A1 (fr) 2002-03-29 2003-10-09 Eisai Co., Ltd. Derive de (1-indanone)-(1,2,3,6-tetrahydropyridine)
WO2003101458A1 (en) * 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2004058258A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2007129427A1 (ja) * 2006-05-08 2007-11-15 Teikoku Seiyaku Co., Ltd. 抗認知症薬物の経皮吸収製剤
AU2007258553A1 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
KR101627901B1 (ko) * 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
EP2931276A1 (en) 2015-10-21
LT2931276T (lt) 2018-04-10
UA114016C2 (xx) 2017-04-10
ES2663680T3 (es) 2018-04-16
SG11201504483YA (en) 2015-07-30
CL2015001615A1 (es) 2015-08-07
JP2016502990A (ja) 2016-02-01
AR125920A2 (es) 2023-08-23
IL239192A0 (en) 2015-07-30
CN104853755A (zh) 2015-08-19
ZA201504274B (en) 2016-11-30
CY1120098T1 (el) 2018-12-12
ECSP15023182A (es) 2015-12-31
AU2013357308A1 (en) 2015-06-18
BR112015013675B1 (pt) 2022-04-26
PE20151026A1 (es) 2015-07-11
WO2014090929A1 (en) 2014-06-19
EA028300B1 (ru) 2017-10-31
CN104853755B (zh) 2017-08-22
CA2893468C (en) 2021-01-12
MX2015007269A (es) 2015-08-12
AU2013357308B2 (en) 2017-08-31
NZ708595A (en) 2019-06-28
DOP2015000133A (es) 2015-11-30
BR112015013675A2 (pt) 2017-07-11
MA38253A1 (fr) 2017-02-28
CA2893468A1 (en) 2014-06-19
RU2015122256A (ru) 2017-01-16
MX362886B (es) 2019-02-22
EA201590932A1 (ru) 2015-10-30
KR102171152B1 (ko) 2020-10-29
NO2970700T3 (es) 2018-05-26
PH12015501302A1 (en) 2016-02-01
HUE036280T2 (hu) 2018-06-28
PT2931276T (pt) 2018-03-19
JP6257641B2 (ja) 2018-01-10
RS56949B1 (sr) 2018-05-31
US9211288B2 (en) 2015-12-15
SI2931276T1 (en) 2018-05-31
NI201500078A (es) 2016-02-15
DK2931276T3 (en) 2018-03-26
IL239192B (en) 2019-03-31
GEP201706739B (en) 2017-09-25
KR20150095681A (ko) 2015-08-21
PL2931276T3 (pl) 2018-06-29
HK1212601A1 (zh) 2016-06-17
MY171802A (en) 2019-10-30
HRP20180333T1 (hr) 2018-04-06
AP2015008498A0 (en) 2015-05-31
EP2931276B1 (en) 2018-02-21
TN2015000235A1 (en) 2016-10-03
GT201500143A (es) 2016-01-22
US20150297585A1 (en) 2015-10-22
RU2635528C2 (ru) 2017-11-13
ME03029B (me) 2018-10-20
MA38253B1 (fr) 2017-10-31
CR20150303A (es) 2016-07-07
PH12015501302B1 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso

Legal Events

Date Code Title Description
FC Refusal